Studies on SP-26, the company’s proprietary time-release ketamine, show positive results in reducing neuropathic nerve pain
ENGLEWOOD CLIFFS, NJ, Oct. 10, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. SILO (“the Company”), a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has completed a preclinical toxicity study of its novel, dose-controlled, sustained-release formulation of ketamine, designated SP-26 is initiated. to treat fibromyalgia.
Eric Weisblum, CEO of Silo Pharma, commented, “We are working closely with our joint venture partner, Zylö Therapeutics, to develop a sustained-release topical ketamine using Z-pod™ technology. Pre-clinical studies have already shown that our jointly developed delivery method and formulation can hold and distribute ketamine in a time-released manner. SP-26 has reported positive results in reducing neuropathic nerve pain. This safety assessment study will uncover maximum tolerated dose data that will inform our future studies.”
In the safety evaluation study, the tolerability of the SP-26 compound will be determined in a minipig study using an ascending (descending) dosing regimen. Data from the study are expected in the first quarter of 2023.
silo pharma recently announced that it is working with a regulatory partner to prepare an FDA Pre-Investigational New Drug (IND) package for SP-26. The Company intends to pursue a 505(b)(2) regulatory pathway for the drug candidate.
About Silo Pharma
silo pharma. Inc. is a development-stage biopharmaceutical company focused on bringing together traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research that we believe will transform the well-being of patients and the healthcare industry. For more information visit
